Absci

Absci has announced that the first volunteers have now been dosed in its Phase 1/2a HEADLINE trial evaluating ABS-201, a novel anti-prolactin receptor (PRLR) antibody designed with the company’s generative AI platform. What is Absci? Absci is a biotech company focused on using generative AI and synthetic biology to design next-generation biologics. Their pitch is…